176 related articles for article (PubMed ID: 34278551)
1. Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.
Puzniak L; Dillon R; Palmer T; Collings H; Enstone A
Infect Dis Ther; 2021 Sep; 10(3):1227-1252. PubMed ID: 34278551
[TBL] [Abstract][Full Text] [Related]
2. Real-world use of ceftolozane/tazobactam: a systematic literature review.
Puzniak L; Dillon R; Palmer T; Collings H; Enstone A
Antimicrob Resist Infect Control; 2021 Apr; 10(1):68. PubMed ID: 33832545
[TBL] [Abstract][Full Text] [Related]
3. Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial.
Lodise T; Yang J; Puzniak LA; Dillon R; Kollef M
Infect Dis Ther; 2020 Dec; 9(4):953-966. PubMed ID: 32996064
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.
Martin-Loeches I; Bruno CJ; DeRyke CA
Future Microbiol; 2024; 19(6):465-480. PubMed ID: 38252038
[TBL] [Abstract][Full Text] [Related]
5. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Timsit JF; Huntington JA; Wunderink RG; Shime N; Kollef MH; Kivistik Ü; Nováček M; Réa-Neto Á; Martin-Loeches I; Yu B; Jensen EH; Butterton JR; Wolf DJ; Rhee EG; Bruno CJ
Crit Care; 2021 Aug; 25(1):290. PubMed ID: 34380538
[TBL] [Abstract][Full Text] [Related]
6. Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Martin-Loeches I; Timsit JF; Kollef MH; Wunderink RG; Shime N; Nováček M; Kivistik Ü; Réa-Neto Á; Bruno CJ; Huntington JA; Lin G; Jensen EH; Motyl M; Yu B; Gates D; Butterton JR; Rhee EG
J Antimicrob Chemother; 2022 Mar; 77(4):1166-1177. PubMed ID: 35022730
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Naik J; Puzniak L; Critchlow S; Elsea D; Dillon RJ; Yang J
Infect Dis Ther; 2021 Jun; 10(2):939-954. PubMed ID: 33837518
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Kollef MH; Timsit JF; Martin-Loeches I; Wunderink RG; Huntington JA; Jensen EH; Yu B; Bruno CJ
Crit Care; 2022 Dec; 26(1):373. PubMed ID: 36457059
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial.
Martin-Loeches I; Shorr AF; Wunderink RG; Kollef MH; Timsit JF; Yu B; Huntington JA; Jensen E; Bruno CJ
Ann Intensive Care; 2023 Feb; 13(1):8. PubMed ID: 36773112
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.
Jorgensen SCJ; Trinh TD; Zasowski EJ; Lagnf AM; Simon SP; Bhatia S; Melvin SM; Steed ME; Finch NA; Morrisette T; Estrada SJ; Rosenberg JR; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932379
[TBL] [Abstract][Full Text] [Related]
11. Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
Feng HP; Patel YT; Zhang Z; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda C; Gao W
J Clin Pharmacol; 2023 Feb; 63(2):166-171. PubMed ID: 36046982
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP).
Huntington JA; Yu B; Li L; Jensen E; Bruno C; Boakye M; Zhang Z; Gao W; Feng HP; Rhee E
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988827
[TBL] [Abstract][Full Text] [Related]
13. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Bassetti M; Castaldo N; Cattelan A; Mussini C; Righi E; Tascini C; Menichetti F; Mastroianni CM; Tumbarello M; Grossi P; Artioli S; Carannante N; Cipriani L; Coletto D; Russo A; Digaetano M; Losito AR; Peghin M; Capone A; Nicolè S; Vena A;
Int J Antimicrob Agents; 2019 Apr; 53(4):408-415. PubMed ID: 30415002
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Gao W; Patel YT; Zhang Z; Johnson MG; Fiedler-Kelly J; Bruno CJ; Rhee EG; Anda C; Feng HP
J Clin Pharmacol; 2023 Mar; 63(3):352-357. PubMed ID: 36201105
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Shorr AF; Bruno CJ; Zhang Z; Jensen E; Gao W; Feng HP; Huntington JA; Yu B; Rhee EG; De Anda C; Basu S; Kollef MH
Crit Care; 2021 Oct; 25(1):354. PubMed ID: 34600585
[TBL] [Abstract][Full Text] [Related]
16. Ceftolozane/Tazobactam for Resistant Drugs
Giaccari LG; Pace MC; Passavanti MB; Gargano F; Aurilio C; Sansone P
Life (Basel); 2021 May; 11(6):. PubMed ID: 34073847
[TBL] [Abstract][Full Text] [Related]
17. Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant
Rodríguez-Núñez O; Periañez-Parraga L; Oliver A; Munita JM; Boté A; Gasch O; Nuvials X; Dinh A; Shaw R; Lomas JM; Torres V; Castón J; Araos R; Abbo LM; Rakita R; Pérez F; Aitken SL; Arias CA; Martín-Pena ML; Colomar A; Núñez MB; Mensa J; Martínez JA; Soriano A
Open Forum Infect Dis; 2019 Oct; 6(10):ofz416. PubMed ID: 31660373
[TBL] [Abstract][Full Text] [Related]
18. The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012-2019.
Zilberberg MD; Nathanson BH; Puzniak LA; Dillon RJ; Shorr AF
BMC Infect Dis; 2022 Oct; 22(1):775. PubMed ID: 36199012
[TBL] [Abstract][Full Text] [Related]
19. Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections.
Holger DJ; Rebold NS; Alosaimy S; Morrisette T; Lagnf A; Belza AC; Coyne AJK; El Ghali A; Veve MP; Rybak MJ
Infect Dis Ther; 2022 Oct; 11(5):1965-1980. PubMed ID: 36048335
[TBL] [Abstract][Full Text] [Related]
20. Machine learning to identify risk factors associated with the development of ventilated hospital-acquired pneumonia and mortality: implications for antibiotic therapy selection.
Sophonsri A; Lou M; Ny P; Minejima E; Nieberg P; Wong-Beringer A
Front Med (Lausanne); 2023; 10():1268488. PubMed ID: 38170135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
